Scarica l'app Stockscreener
7.2978
2.80%
-0.2122
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXST Giù?
Forum
Previsione
Precedente Chiudi:
$7.51
Aprire:
$7.45
Volume 24 ore:
90,584
Relative Volume:
0.10
Capitalizzazione di mercato:
$301.24M
Reddito:
$142.09M
Utile/perdita netta:
$-35.73M
Rapporto P/E:
-8.31
EPS:
-0.8782
Flusso di cassa netto:
$-22.20M
1 W Prestazione:
-7.94%
1M Prestazione:
-9.09%
6M Prestazione:
-22.51%
1 anno Prestazione:
-71.31%
Intervallo 1D:
$7.22
$7.57
Intervallo di 1 settimana:
$6.825
$8.08
Portata 52W:
$6.32
$27.13
Rxsight Inc Stock (RXST) Company Profile
Nome
Rxsight Inc
Settore
Industria
Telefono
949-521-7822
Indirizzo
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
7.30 | 309.91M | 142.09M | -35.73M | -22.20M | -0.8782 |
|
ABT
Abbott Laboratories
|
110.17 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
343.04 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
88.94 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
68.88 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
84.60 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Iniziato | William Blair | Mkt Perform |
| 2025-07-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | Downgrade | Jefferies | Buy → Hold |
| 2025-07-09 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-07-09 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-07-09 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | Iniziato | Piper Sandler | Neutral |
| 2025-04-09 | Downgrade | UBS | Buy → Neutral |
| 2025-04-04 | Downgrade | JP Morgan | Overweight → Underweight |
| 2025-04-03 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-12-20 | Downgrade | Stifel | Buy → Hold |
| 2024-12-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-10-29 | Iniziato | Jefferies | Buy |
| 2024-08-20 | Reiterato | Needham | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-05-07 | Reiterato | BTIG Research | Buy |
| 2023-12-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | Iniziato | Stifel | Buy |
| 2023-12-04 | Iniziato | Morgan Stanley | Overweight |
| 2023-04-13 | Iniziato | Oppenheimer | Outperform |
| 2022-12-12 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | Iniziato | Needham | Buy |
Mostra tutto
Rxsight Inc Borsa (RXST) Ultime notizie
(RXST) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Stifel Nicolaus Has Lowered Expectations for RxSight (NASDAQ:RXST) Stock Price - MarketBeat
Stifel cuts RxSight stock price target to $9 on revenue guidance - Investing.com
RxSight Inc. (RXST) PT Lowered to $9 at Stifel After Prudent Guidance - StreetInsider
RxSight Earnings Call: Strong Core, Cautious Outlook - TipRanks
How The RxSight (RXST) Investment Story Is Shifting With New Guidance And CFO Change - Yahoo Finance
Midday Stock Roundup: Staar Falls 3.8% After Q4 Miss - Orange County Business Journal
Forecast Cut: Will RxSight Inc stock go up in YEARJuly 2025 Outlook & High Return Stock Watch Alerts - baoquankhu1.vn
RxSight (RXST) Q4 2025 Earnings Call Transcript - AOL.com
RxSight (RXST) COO granted 32,218 RSUs vesting through 2029 - Stock Titan
2026-03-03 | RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:RXST | Press Release - Stockhouse
RXST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Short Interest in RxSight, Inc. (NASDAQ:RXST) Expands By 29.3% - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2026-03-01 | Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Shareholders to Inquire about Securities Investigation | NDAQ:RXST | Press Release - Stockhouse
Artisan Partners Limited Partnership Cuts Position in RxSight, Inc. $RXST - MarketBeat
RXST Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
RxSight, Inc. (RXST) Investor Outlook: Exploring a 28% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
RxSight, Inc. (NASDAQ:RXST) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), RxSight (RXST) and Cardiff Oncology (CRDF) - The Globe and Mail
RxSight Reports Fourth Quarter and Fiscal Year Financial Results - VisionMonday.com
Responsive Playbooks and the RXST Inflection - Stock Traders Daily
Needham reiterates Buy on RxSight stock, keeps $13 target By Investing.com - Investing.com Australia
RxSight (RXST) Loss Deepens In Q4 Results Reinforcing Bearish Profitability Narratives - simplywall.st
What 5 Analyst Ratings Have To Say About RxSight - Benzinga
UBS Increases Price Target for RXST to $9.00 While Maintaining N - GuruFocus
RxSight (NASDAQ:RXST) Given New $9.00 Price Target at UBS Group - MarketBeat
RXST: Piper Sandler Lowers Price Target to $10.00, Maintains Neu - GuruFocus
RxSight (NASDAQ:RXST) Price Target Lowered to $10.00 at Piper Sandler - MarketBeat
UBS Adjusts Price Target on RxSight to $9 From $8, Maintains Neutral Rating - marketscreener.com
RxSight, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Needham Reiterates Buy Rating on RxSight Inc. (RXST) - StreetInsider
RxSight Q4 Earnings Call Highlights - MarketBeat
RxSight (NASDAQ:RXST) Issues Earnings Results - MarketBeat
RxSight, Inc. (RXST) Posts Fourth Quarter Loss, Surpasses Revenue Expectations - Bitget
Earnings call transcript: RxSight Q4 2025 beats EPS, revenue forecasts - Investing.com
RxSight, Inc. (RXST) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: RxSight Q4 2025 beats EPS, revenue forecasts By Investing.com - Investing.com Australia
RXSIGHT INC (NASDAQ:RXST) Reports Q4 Beat but Cautious 2026 Outlook Weighs on Shares - ChartMill
Rxsight earnings beat by $0.32, revenue topped estimates - Investing.com Canada
RxSight, Inc. (RXST) Tops Q4 EPS by 32c - StreetInsider
RxSight (RXST) Releases Q4 2025 Earnings: Revenue Down but Beats Estimates; Loss Narrows, EPS Beats - Quiver Quantitative
RxSight, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance - The Manila Times
RxSight (RXST) grows LAL volume but posts wider 2025 loss, soft 2026 outlook - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect - Stockhouse
Earnings Update: Will RxSight Inc face regulatory challenges2025 Year in Review & Low Drawdown Trading Strategies - baoquankhu1.vn
Earnings To Watch: RxSight Inc (RXST) Reports Q4 2025 Result - GuruFocus
Analyst Calls: Can ProQR Therapeutics NV withstand a market correctionBuy Signal & Daily Momentum Trading Reports - baoquankhu1.vn
2026-02-22 | Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Stockholders to Inquire about Securities Investigation | NDAQ:RXST | Press Release - Stockhouse
RxSight, Inc. (RXST) initiated at market perform as firm seeks sales reacceleration - MSN
Rxsight Inc Azioni (RXST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.61%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):